ARC Pharmaceuticals Inc. Receives US Patent
"This issued patent strengthens ARC's intellectual property portfolio," said Dr. Chuck Winternitz, Director of Operations for ARC. "The polymers included broaden the Company's pipeline and may be useful in the development of films, gels and instillates for the treatment of surgical adhesion disease."
Surgical adhesions cause dysfunction and pain in millions of patients worldwide. It is a complex inflammatory disorder in which tissues that normally remain separated in the body grow into each other, usually as a response of the tissues to surgical trauma. Currently marketed products for the prevention of surgical adhesions, such as films, gels and sprays, are both difficult to apply and only marginally effective. ARC's revolutionary technology combines ease of use, decreased surgery time and effectiveness.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.